Global Inotropic Agents Market, By Type (Positive Inotropic Drugs, Negative Inotropic Drugs, Others), Indication (Heart Attack, Heart Failure, Angina, Arrhythmia, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Inotropic Agents Market Analysis and Size
The global inotropic agents market is expected to witness significant growth during the forecast period. These agents are largely confined to critically ill patients with haemodynamic impairment in a way that tissue blood flow is insufficient to meet metabolic requirements. Increased cardiac diseases and surgeries are increasing the inotropic agents' growth. Many major market players are contributing a lot in drug discovery and development. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global inotropic agents market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Inotropic agents are used to treat low cardiac output-associated diseases such as cardiogenic shock after a heart attack, severe heart failure, or sometimes after a cardiac surgery. These agents affects the contraction of the heart muscle. Inotropic agents increase calcium release from the sarcoplasmic reticulum or increase the influx of calcium into the heart muscle cell. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Inotropic Agents Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Positive Inotropic Drugs, Negative Inotropic Drugs, Others), Indication (Heart Attack, Heart Failure, Angina, Arrhythmia, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), GSK plc (UK), Novartis AG (Switzerland), Mylan N.V. (U.S.), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Cadila Pharmaceuticals (India), Lilly (U.S.), Cipla Inc. (U.S.), Aurobindo Pharma (India), Lupin (India), Covis Pharma GmbH (Switzerland)
|
|
Market Opportunities
|
|
Global Inotropic Agents Market Dynamics
Drivers
- Increase in Cardiovascular Diseases
According to the WHO, around 60% - 85% of population have adopted a sedentary life. According to CDC, approximately 31 million adults aged over 50 years lives a sedentary life, and only 1 out of 4 U.S. adults meets the appropriate need of physical activity. As a result, inotropic agents are used in this process. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increasing Demand for Retail Pharmacies
The rise in the number of inotropic agents delivered through these retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Increased Use in Major Surgeries
In many major surgeries, anaesthetists commonly use various mild inotropic or vasopressor agents in huge doses to accurate the cardiovascular effects of general and regional anaesthesia. Ephedrine, phenylephrine and metaraminol are the most common options for this indication. In addition, inotropic agents are being widely chosen for haemodynamic therapy with pre-determined goals, including cardiac index, systemic oxygen delivery and/or venous saturation. This creates much opportunity for the market growth.
Restraints/Challenges
- Complications of Inotropic Agents
Some common side effects of keratolytic agents include arrhythmias, tachycardia, hypotension, hypertension, anxiety, fever. Thus, it creates hindrance to the market growth.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This global inotropic agents market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global inotropic agents market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Inotropic Agents Market
The covid-19 pandemic negatively impacted the global antacids market because the utmost priority was given to Covid-19 patients for treatment. The COVID-19 pandemic caused a tremendous increase in its sales, as most of the population were stressed, with improper diet and minimal exercise. In addition to this, several keratolytic agents were successful in treating many COVID-19 patients who were hospitalized. Thus, the COVID-19 outbreak increased the keratolytic agents market’s growth globally.
Global Inotropic Agents Market Scope
The global inotropic agents market is segmented on the basis of indication, type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Heart Attack
- Heart Failure
- Angina
- Arrhythmia
- Others
Type
- Positive Inotropic Drugs
- Epinephrine
- Norepinephrine
- Dopamine
- Negative Inotropic Drugs
- Verapamil
- Cibenzoline
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Inotropic Agents Market Regional Analysis/Insights
The global inotropic agents market is analysed and market size insights and trends are provided by indication, type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global inotropic agents market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to increasing initiatives taken by the pharmaceutical organizations to generate novel formulation.
Asia-Pacific dominates the market due increasing hypertension and diabetes patients and increased prevalence of cardiac diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Inotropic Agents Market Share Analysis
The global inotropic agents market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global inotropic agents market.
Key players operating in the global inotropic agents market include:
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Cadila Pharmaceuticals (India)
- Lilly (U.S.)
- Cipla Inc. (U.S.)
- Aurobindo Pharma (India)
- Lupin (India)
- Covis Pharma GmbH (Switzerland)
SKU-